Search
forLearn
5 / 801 resultslearn Trichogen
learn PTT-6®
learn GHK-Cu Copper Tripeptide
learn PTD-DBM
Research
5 / 132 results
research Baldness, acne and testicular germ cell tumours
Men with testicular cancer were less likely to experience baldness and severe acne.
research Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis
Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.
research Association between male pattern baldness and testicular germ cell tumor: a meta-analysis
Baldness may lower the risk of testicular cancer.
research Postnatal determinants of testicular germ cell tumor by histological subtypes: The EPSAM1 and EPSAM2 studies
Childhood and adult height, and early immune-related hospitalizations increase testicular cancer risk, while baldness, larger families, and sports reduce it.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
Community Join
5 / 1000+ resultscommunity GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Where is GT20029 already? Grrrr
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
community Where can I find the results of GT20029 phase 1 study in the US/China. The actual data
The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.
community What is preventing GT20029 from being the cure to androgenetic hair loss?
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
community GT20029 phase II results release date?
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.